Answer
The mean terminal plasma half-life of talazoparib (Talzenna) in patients with cancer is 90 hours (standard deviation ±58 hours).
Sources for this answer
- Talzenna 1mg Hard CapsulesPfizer Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 10Document updated
Sources checked